Adocia (XPAR:ADOC) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


XPAR:ADOC Adocia XPAR:ADOC
30 GF Score
Price €3.94
GF Value €0.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Adocia Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Adocia's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

XPAR:ADOC vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Adocia's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adocia Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adocia's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Adocia's Margin of Safety % (DCF FCF Based) falls into.


XPAR:ADOC
30GF Score
Adocia XPAR:ADOC
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adocia (XPAR:ADOC) Overvalued in 2026?

Based on GuruFocus' analysis, Adocia stock appears to be overvalued. The current stock price of €3.94 is trading 332.7% above its estimated GF Value™ of €0.91. GuruFocus considers Adocia to be Significantly Overvalued.

Key valuation signals for XPAR:ADOC:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €0.91 vs. price of €3.94 (332.7% above fair value)
  • GF Score™: 30/100 with 7 warning signs

No single metric tells the full story. See the XPAR:ADOC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adocia Business Description

Other Exchanges 0QAI:UKA89:Germany
Address 115 Avenue Lacassagne, Lyon, FRA, 69003
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
30GF Score

Get the complete analysis for XPAR:ADOC

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94
Price
€0.91
GF Value